Literature DB >> 20832296

Advances in cancer surgery: natural orifice surgery (NOTES) for oncological diseases.

Erwin Rieder1, Lee L Swanstrom.   

Abstract

Natural orifice transluminal endoscopic surgery (NOTES) is a new concept that attempts to reduce the impact of surgery on the patient. In surgical oncology several studies have already revealed that a minimally invasive approach provides at least the same, if not a better, long-term outcome. One could hypothesize that a less invasive approach such as NOTES could further enhance such advantages. Since its initial description, NOTES has become clinical reality and today nearly every organ is accessible by a transluminal approach, in at least the experimental setting. Subsequent to published research, first clinical studies on NOTES in oncology were reported and the accuracy of transgastric peritoneoscopy for staging of pancreas cancer was shown to be similar to laparoscopy in humans. A NOTES gastro-jejunostomy via transgastric access has also been proposed to decrease invasiveness of palliative treatment of duodenal, biliary and pancreatic cancers. Colorectal cancer resection via transanal access would offer a clear-cut patient advantage over laparoscopic and would not be subject to the frequent criticism of violating an innocent second organ, as the colon or rectum is always breached in a colectomy. Natural orifice endoluminal therapies, such as endoscopic submucosal dissection, already have been clinically applied for several years. Improved techniques or instruments evolving from NOTES technology might enhance its widespread use for the treatment of early malignancies and thereby again will provide a tremendous benefit for the patient. Although still somewhat controversial, the subject of natural orifice surgery in oncological disease indicates that current laboratory efforts to introduce NOTES into cancer surgery could be ready for cautious clinical investigations. The final determination of patient benefit will need well-constructed prospective study.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20832296     DOI: 10.1016/j.suronc.2010.07.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

1.  Impact of formal training in endoscopic submucosal dissection for early gastrointestinal cancer: A systematic review and a meta-analysis.

Authors:  Miguel A Tanimoto; M Lourdes Guerrero; Yoshinori Morita; Jonathan Aguirre-Valadez; Elisa Gomez; Carlos Moctezuma-Velazquez; Jose A Estradas-Trujillo; Miguel A Valdovinos; Luis F Uscanga; Rikiya Fujita
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

2.  A natural orifice transrectal approach for oncologic resection of the rectosigmoid: an experimental study and comparison with conventional laparoscopy.

Authors:  Erwin Rieder; Georg O Spaun; Yash S Khajanchee; Danny V Martinec; Brittany N Arnold; Ann E Smith Sehdev; Lee L Swanstrom; Mark H Whiteford
Journal:  Surg Endosc       Date:  2011-05-10       Impact factor: 4.584

3.  Feasibility of needlescopic surgery for colorectal cancer: safety and learning curve for Japanese Endoscopic Surgical Skill Qualification System-unqualified young surgeons.

Authors:  Hisanori Miki; Yosuke Fukunaga; Toshiya Nagasaki; Takashi Akiyoshi; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Masashi Ueno
Journal:  Surg Endosc       Date:  2019-05-13       Impact factor: 4.584

4.  Transgastric pure-NOTES peritoneoscopy and endoscopic ultrasonography for staging of gastrointestinal cancers: a survival and feasibility study.

Authors:  Anders Meller Donatsky; Peter Vilmann; Søren Meisner; Lars Nannestad Jørgensen; Jacob Rosenberg
Journal:  Surg Endosc       Date:  2011-12-17       Impact factor: 4.584

5.  Needlescopic surgery for left-sided colorectal cancer.

Authors:  Toshiki Mukai; Yosuke Fukunaga; Masashi Ueno; Satoshi Nagayama; Yoshiya Fujimoto; Tsuyoshi Konishi; Takashi Akiyoshi; Riki Ono; Toshiharu Yamaguchi
Journal:  Int J Colorectal Dis       Date:  2014-09-17       Impact factor: 2.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.